AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Calendar Export
Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication
(ID 502)
Lecture Time
12:30 - 12:30
Session Name
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
All Speakers
(na, Switzerland)
Authors
All Speakers
(na, Switzerland)